JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

  NCT03817853

  Condition:   Advanced Follicular Lymphoma
  Interventions:   Drug: Obinutuzumab;   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone/Prednisolone/Methylprednisolone;   Drug: Vincristine
  Sponsor:   Hoffmann-La Roche
  Recruiting
• National Cardiogenic Shock Initiative

  NCT03677180

  Conditions:   Cardiogenic Shock;   Acute Myocardial Infarction;   STEMI - ST Elevation Myocardial Infarction;   NSTEMI - Non-ST Segment Elevation MI;   Heart Attack
  Intervention:  
  Sponsors:   Henry Ford Health System;   Abiomed Inc.;   Chiesi Farmaceutici S.p.A.
  Recruiting
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  NCT03652064

  Condition:   Multiple Myeloma
  Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

  NCT03428217

  Conditions:   Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
  Interventions:   Drug: CB-839;   Drug: Cabozantinib;   Drug: Placebo
  Sponsor:   Calithera Biosciences, Inc
  Recruiting
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565

  Condition:   Multiple Myeloma
  Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

  NCT03409614

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Drug: REGN2810;   Drug: REGN2810/chemo/ipi;   Other: Chemotherapy;   Drug: Placebo
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

  NCT03307785

  Conditions:   Metastatic Cancer;   Advanced Cancer;   Solid Tumor;   Non Small Cell Lung Cancer Metastatic;   Non Small Cell Lung Cancer Stage IIIB;   Non Small Cell Lung Cancer
  Interventions:   Drug: Niraparib;   Drug: TSR-042;   Drug: Carboplatin-Paclitaxel;   Drug: Bevacizumab;   Drug: TSR-022;   Drug: Carboplatin Pemetrexed;   Drug: Carboplatin-Nab-Paclitaxel
  Sponsor:   Tesaro, Inc.
  Recruiting
• Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

  NCT03263026

  Condition:   Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Enzastaurin Hydrochloride;   Other: R-CHOP + placebo
  Sponsor:   Denovo Biopharma LLC
  Recruiting
• An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  NCT03170882

  Condition:   Relapsed and/or Refractory Multiple Myeloma
  Interventions:   Drug: Ixazomib;   Drug: Pomalidomide;   Drug: Dexamethasone
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

  NCT02817633

  Condition:   Advanced or Metastatic Solid Tumors
  Interventions:   Drug: TSR-022;   Drug: TSR-042, an anti-PD-1 antibody;   Drug: TSR-033, an anti-LAG-3 antibody
  Sponsor:   Tesaro, Inc.
  Recruiting
• Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

  NCT02793583

  Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
  Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

  NCT02715284

  Condition:   Advanced or Metastatic Solid Tumors
  Intervention:   Biological: TSR-042
  Sponsor:   Tesaro, Inc.
  Recruiting
• A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

  NCT02599324

  Conditions:   Metastatic Renal Cell Carcinoma;   Advanced Urothelial Carcinoma;   Advanced Gastric Adenocarcinoma;   Metastatic Colorectal Adenocarcinoma
  Interventions:   Drug: Ibrutinib;   Drug: Everolimus;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Cetuximab;   Drug: Pembrolizumab
  Sponsor:   Pharmacyclics LLC.
  Recruiting
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

  NCT02091141

  Conditions:   Neoplasms;   Solid Tumors;   Biliary Cancer;   Salivary Cancer;   Bladder Cancer
  Interventions:   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Erlotinib;   Drug: Vemurafenib;   Drug: Cobimetinib;   Drug: Vismodegib;   Drug: Alectinib;   Drug: Atezolizumab
  Sponsor:   Genentech, Inc.
  Recruiting